Search
Romidepsin
go.drugbank.com/drugs/DB06176ApprovedInvestigationalRomidepsin is a selective inhibitor of histone deacetylase, approved in the US in 2009 for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesLow affinity immunoglobulin gamma Fc region receptor III-B
go.drugbank.com/bio_entities/BE0000901TargetHumansReceptor for the Fc region of immunoglobulins gamma. Low affinity receptor. Binds complexed or aggregated IgG and also monomeric IgG. … May serve as a trap for immune complexes in the peripheral circulation which does not activate neutrophils
Polypeptides: Low affinity immunoglobulin gamma Fc region receptor III-BSynonyms: IgG Fc receptor III-1Low affinity immunoglobulin gamma Fc region receptor II-b
go.drugbank.com/bio_entities/BE0002099TargetHumansReceptor for the Fc region of complexed or aggregated immunoglobulins gamma. Low affinity receptor. … Binding to this receptor results in down-modulation of previous state of cell activation triggered via antigen receptors on B-cells (BCR), T-cells (TCR) or via another Fc receptor.
Polypeptides: Low affinity immunoglobulin gamma Fc region receptor II-bSynonyms: IgG Fc receptor II-bTransient receptor potential cation channel subfamily V member 6
go.drugbank.com/bio_entities/BE0005102TransporterTargetHumansInactivation includes both a rapid Ca(2+)-dependent and a slower Ca(2+)-calmodulin-dependent mechanism; the latter may be regulated by phosphorylation.
Polypeptides: Transient receptor potential cation channel subfamily V member 6Transient receptor potential cation channel subfamily M member 5
go.drugbank.com/bio_entities/BE0020643TargetHumansMonovalent cation-selective ion channel activated by intracellular Ca(2+) in a voltage- and temperature-dependent manner (PubMed:14634208). Mediates the transport of Na(+), K(+) and Cs(+) ions equally well (PubMed:14634208). Activated di...
Polypeptides: Transient receptor potential cation channel subfamily M member 5Synonyms: Long transient receptor potential channel 5Magaldrate
go.drugbank.com/drugs/DB08938ApprovedInvestigationalWithdrawnMagaldrate is an antacid drug used for the treatment of esophagitis, duodenal and gastric ulcers, and gastroesophageal reflux. Magaldrate has been discontinued in the US market.
Categories: Drugs for Acid Related DisordersErgotamine
go.drugbank.com/drugs/DB00696ApprovedIt is an alpha-1 selective adrenergic agonist and is commonly used in the treatment of migraine disorders.
Mixtures: Cafergot Pb Tab, Cafergot Pb SupCategories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesElinzanetant
go.drugbank.com/drugs/DB18968ApprovedInvestigational[L53798] Later the same year, it was approved in the US for the same indication. [L54216] … Elinzanetant is a non-hormonal, selective, dual neurokinin 1 (NK-1) and 3 (NK-3) receptor antagonist.
Categories: Substance P/Neurokinin-1 Receptor Antagonist, Cytochrome P-450 CYP3A InhibitorsClevidipine
go.drugbank.com/drugs/DB04920ApprovedInvestigationalClevidipine is a dihydropyridine L-type calcium channel blocker that is selective for vascular smooth muscle and is indicated for blood pressure reduction when oral therapy is not an option.
Categories: Antihypertensive Agents Indicated for Hypertension, Cytochrome P-450 SubstratesProducts: Cleviprex 0,5 mg/ml Emulsion zur InjektionLecanemab
go.drugbank.com/drugs/DB14580ApprovedInvestigational[A253962,L44547] On January 6, 2023, lecanemab was granted accelerated approval by the FDA for the treatment of Alzheimer’s Disease.[L44547] It was granted full FDA approval on July 6, 2023.